Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AFMD | US
-0.02
-0.60%
Healthcare
Biotechnology
30/06/2024
17/10/2024
3.31
3.40
3.40
3.25
Affimed N.V. a clinical-stage biopharmaceutical company focuses on discovering and developing cancer immunotherapies in the United States Germany and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma Phase II clinical trial for hodgkin lymphoma and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24 a tetravalent bispecific epidermal growth factor receptor and CD16A-binding innate cell engager which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28 an innate cell engager (ICE) which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32 an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules including AFM32 in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg Germany.
View LessValue Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
48.0%1 month
48.7%3 months
48.5%6 months
112.9%-
-
1.50
-
-
1.13
8.28
-
-71.17M
51.90M
51.90M
-
-7.41K
-
-90.00
-124.08
7.14
4.43
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.48
Range1M
1.28
Range3M
2.77
Rel. volume
0.78
Price X volume
246.91K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kronos Bio Inc | KRON | Biotechnology | 0.93 | 56.07M | -3.63% | n/a | 22.03% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.72 | 53.59M | 2.38% | n/a | 4.22% |
OncoCyte Corporation | OCX | Biotechnology | 3.12 | 53.39M | 0.32% | n/a | 16.15% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 9.38 | 53.22M | 1.96% | n/a | -81.03% |
Syros Pharmaceuticals Inc | SYRS | Biotechnology | 1.95 | 53.09M | 2.09% | n/a | -954.99% |
Aadi Bioscience Inc | AADI | Biotechnology | 2.15 | 52.92M | 0.47% | n/a | 1.34% |
Elicio Therapeutics Inc. | ELTX | Biotechnology | 4.77 | 51.39M | 0.42% | 5.20 | -388.56% |
Fortress Biotech Inc | FBIO | Biotechnology | 1.81 | 49.89M | 3.43% | n/a | 494.61% |
CollPlant Holdings Ltd | CLGN | Biotechnology | 4.28 | 49.03M | -5.10% | n/a | 0.00% |
Rafael Holdings Inc | RFL | Biotechnology | 1.97 | 48.40M | -3.90% | n/a | 2.77% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.13 | 0.53 | Expensive |
Ent. to Revenue | 8.28 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 1.50 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 48.51 | 72.92 | Lower Risk |
Debt to Equity | - | -1.24 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 51.90M | 3.78B | Emerging |